ARCHIVES

Cyramza-Docetaxel Combination Extends OS In Second-Line NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI Ponders How Extra $40 Million Will Be Spent, Will Submit Plans to NCAB At Upcoming Meeting

January 14, 1983

NCAB Votes No To Funding Diet FIT, Citing NCI Resources

December 8, 1989

Amgen Says It Can Demonstrate Safety of Existing Hg Target.

March 16, 2007

Zaltrap Economics 101: The Pricing And Repricing of an Expensive Drug

November 16, 2012

Organ Systems Programs “Filling the Gaps” With Targeted Research

January 23, 1987

Nurse Oncology Society Growing, developing Care Guidelines

August 19, 1977